GlassScriptPhysician profile
Michael Amoashiy
NPI 1346354982
$40,443.04
in general payments reported to CMS, 2019-2025
80 companies · $4,829 in 2025
The $4,829 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,102 · 2020: $3,046 · 2021: $5,978 · 2022: $6,589 · 2023: $7,160 · 2024: $8,739 · 2025: $4,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20,413.68 |
| Education | $314.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,401.30 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Ucb, INC. | $2,948.12 | 2019-2025 | Briviact, Nayzilam |
| Neurocrine Biosciences, INC. | $2,257.17 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $2,156.61 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Novartis Pharmaceuticals Corporation | $1,611.61 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,555.60 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Kyowa Kirin, INC. | $1,442.70 | 2020-2025 | Nourianz |
| Eisai INC. | $1,394.34 | 2019-2025 | |
| Biogen, INC. | $1,391.21 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,206.34 | 2021-2025 | Caplyta |
| Sk Life Science, INC. | $1,174.03 | 2020-2025 | Xcopri |
| Allergan, INC. | $1,165.20 | 2019-2022 | |
| Mdd US Operations, LLC | $1,128.30 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Amgen INC. | $1,009.10 | 2019-2025 | Aimovig, Uplizna |
| Lilly USA, LLC | $999.72 | 2019-2025 | Emgality, Reyvow, Kisunla |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $875.42 | 2020-2025 | Rexulti, Vyepti, Brintellix |
| Vanda Pharmaceuticals INC. | $691.52 | 2022-2025 | Fanapt, Hetlioz, Ponvory |
| Pfizer INC. | $688.15 | 2019-2025 | |
| Celgene Corporation | $682.62 | 2019-2025 | Zeposia |
| Scilex Pharmaceuticals INC. | $661.83 | 2019-2025 | Ztlido |
| Acadia Pharmaceuticals INC | $652.29 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $582.63 | 2019-2025 | Crexont, Rytary, Ongentys |
| Emd Serono, INC. | $505.75 | 2020-2024 | Mavenclad |
| Catalyst Pharmaceuticals, INC. | $493.54 | 2023-2025 | Fycompa |
| Genentech USA, INC. | $473.46 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $432.56 | 2023-2025 | Auvelity, Symbravo |
| Sumitomo Pharma America, INC. | $419.63 | 2023-2024 | Aptiom |
| Janssen Pharmaceuticals, INC | $412.59 | 2021-2024 | Spravato |
| Endo Pharmaceuticals INC. | $375.82 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $363.47 | 2019-2022 | |
| Horizon Therapeutics Plc | $357.97 | 2021-2023 | Uplizna |
| Neurelis, INC. | $302.20 | 2020-2024 | Valtoco |
| Genzyme Corporation | $297.73 | 2019-2023 | |
| Avion Pharmaceuticals | $286.11 | 2021-2023 | Dhivy |
| Medtronic, INC. | $277.64 | 2021-2025 | Percept PC Brainsense |
| Biohaven Pharmaceuticals, INC. | $252.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.07 | 2019-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $222.60 | 2023-2025 | Quviviq, Quviviq |
| Bausch Health US, LLC | $213.29 | 2019-2020 | |
| Argenx US, INC. | $212.65 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Acorda Therapeutics, INC | $192.21 | 2019-2024 | Inbrija |
| Sunovion Pharmaceuticals INC. | $176.26 | 2021 | |
| Assertio Therapeutics, INC. | $176.14 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $163.25 | 2022-2023 | Seglentis |
| Tg Therapeutics, INC. | $160.72 | 2023-2025 | |
| Adamas Pharmaceuticals, INC. | $153.60 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $146.54 | 2022 | |
| Upsher-Smith Laboratories LLC | $137.93 | 2019-2022 | |
| Almatica Pharma LLC | $130.64 | 2021-2023 | Gralise |
| Supernus Pharmaceuticals, INC. | $126.31 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $123.00 | 2019-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $121.97 | 2020-2025 | Cobenfy |
| Azurity Pharmaceuticals, INC. | $112.30 | 2023-2024 | Horizant, Horizant |
| Grifols USA, LLC | $104.64 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $100.34 | 2024-2025 | Xeomin, Inbrija |
| Ipsen Biopharmaceuticals, INC | $92.15 | 2025 | Dysport |
| Impel Pharmaceuticals INC. | $91.74 | 2023 | Trudhesa |
| Arbor Pharmaceuticals, INC. | $90.27 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $87.07 | 2021 | |
| Validus Pharmaceuticals LLC | $86.73 | 2025 | Equetro, Raldesy |
| Alexion Pharmaceuticals, INC. | $86.38 | 2019-2024 | Ultomiris |
| Saluda Medical Americas, INC. | $84.60 | 2024 | Evoke |
| Averitas Pharma INC. | $83.12 | 2023-2024 | Qutenza |
| Alnylam Pharmaceuticals INC. | $77.74 | 2020-2021 | |
| Grt US Holding, INC. | $75.23 | 2022 | |
| Aimmune Therapeutics, INC. | $74.90 | 2024-2025 | Zenpep |
| Tanabe Pharma America, INC. | $73.87 | 2023 | |
| Greenwich Biosciences, INC. | $73.37 | 2020-2021 | |
| Promius Pharma LLC | $65.90 | 2019 | |
| Boston Scientific Corporation | $60.34 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Vertex Pharmaceuticals Incorporated | $58.90 | 2025 | |
| Corium, LLC | $56.59 | 2023 | Azstarys |
| Medtronic USA, INC. | $33.00 | 2020 | |
| Vertical Pharmaceuticals, LLC | $32.52 | 2019 | |
| Ge Healthcare | $30.02 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $23.65 | 2022 | |
| Abbott Laboratories | $19.32 | 2021 | |
| Tonix Medicines, INC. | $18.06 | 2025 | Zembrace Symtouch |
| Alfasigma USA, INC. | $15.89 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $14.26 | 2020 |
Drugs and devices associated with these payments
Rexulti $1,372Qulipta $1,278Ingrezza $1,178Briviact $964Botox $907Vraylar $855Caplyta $837Leqembi $756Ubrelvy $732Nourianz $681Kesimpta $640Gocovri $613Fanapt $543Fycompa $514Zeposia $456Nurtec Odt $422Aptiom $420Auvelity $402Nuplazid $388Nayzilam $357Nuedexta $347Austedo Xr $260Ongentys $257Ocrevus $226Quviviq $223Ztlido $195Vyvgart Hytrulo $195Percept PC Brainsense $194Vumerity $192Aimovig $186Crexont $182Hetlioz $175Tysabri $174Briumvi $161Ajovy $160Emgality $152Uplizna $152Rytary $150Octagam Immune Globulin (Human) $144Panzyga $144Zavzpret $139Vyepti $132Austedo $132Reyvow $132Kisunla $122Mavenclad $122Horizant $112Ponvory $107Seglentis $99.89Dysport $92.15Trudhesa $91.74Dhivy $86.54Evoke $84.60Amyvid $83.13Qutenza $83.12Xeomin $82.10Zenpep $74.90Radicava Ors $73.87Radicava $73.87Valtoco $73.32Inbrija $71.99Cobenfy $62.31Equetro $62.14Journavx $58.90Azstarys $56.59Ocrevus Zunovo $51.04Spinraza $45.69Spravato $45.55Abilify Maintena $38.31Paxlovid $37.30Comirnaty $37.30Symbravo $30.12Gralise $28.57Raldesy $24.59Elyxyb - Celecoxib $23.63Ultomiris $23.06Brintellix $23.02Wavewriter Alpha Prime 16 $22.47Trintellix $20.01Belsomra $18.80Zembrace Symtouch $18.06Vyvgart $17.66Vyalev $16.23Aubagio $15.38Ongentys 50mg Capsules 30 $14.67Apokyn $10.16Xcopri $1.00
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Amoashiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.